NCT00992732: Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders |
|
|
| Terminated | 2a | 1 | US | HQK-1004, arginine butyrate, Valganciclovir (may substitute with ganciclovir) | HemaQuest Pharmaceuticals Inc. | Lymphoid Malignancies, Lymphoproliferative Disorders | 11/10 | | | |
NCT00917826: Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies |
|
|
| Terminated | 2 | 1 | US | Arginine Butyrate, HQK-1004, Ganciclovir, Valganciclovir | HemaQuest Pharmaceuticals Inc., Boston University | EBV Lymphomas, Lympho-proliferative Diseases | 09/09 | | | |
